BridgeBio Oncology Therapeutics (BBOT) Cash & Current Investments (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Cash & Current Investments for 3 years, with the latest figure at $252.3 million in Q1 2026.

• Quarterly Cash & Current Investments rose 26093.11% year-over-year to $252.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $252.3 million (up 26093.11% YoY) and the FY2025 annual result came in at $425.5 million, up 173.38% from the prior year.
• Cash & Current Investments eased to $252.3 million in Q1 2026 per BBOT's latest filing, from $425.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $468.3 million in Q3 2025 and troughed at $664231.0 in Q2 2025.
• A 3-year average of $145.4 million and a median of $1.8 million in 2024 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 26125.11% in 2025, down 63.39% in 2025.
• Over 3 years, Cash & Current Investments stood at $155.6 million in 2024, then soared by 173.38% to $425.5 million in 2025, then slumped by 40.71% to $252.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $252.3 million, $425.5 million, and $468.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.